Home > Insider Trading > Filing (0001209191-21-058530)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1087294	Cumberland Pharmaceuticals Inc	CPIX	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1632384	C Joseph Galante	2525 West End Avenue Suite 950 Nashville TN 37203		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2021-09-01	142	$2.88	37,955	No	4	P	Direct
Common Stock	Acquisiton	2021-09-02	142	$2.88	38,097	No	4	P	Direct
Common Stock	Acquisiton	2021-09-03	142	$2.85	38,239	No	4	P	Direct
Common Stock	Acquisiton	2021-09-07	142	$2.79	38,381	No	4	P	Direct
Common Stock	Acquisiton	2021-09-08	142	$2.89	38,523	No	4	P	Direct
Common Stock	Acquisiton	2021-09-09	142	$2.77	38,665	No	4	P	Direct
Common Stock	Acquisiton	2021-09-10	142	$2.78	38,807	No	4	P	Direct
Common Stock	Acquisiton	2021-09-13	142	$2.96	38,949	No	4	P	Direct
Common Stock	Acquisiton	2021-09-14	142	$3.02	39,091	No	4	P	Direct
Common Stock	Acquisiton	2021-09-15	142	$2.86	39,233	No	4	P	Direct
Common Stock	Acquisiton	2021-09-16	142	$2.91	39,375	No	4	P	Direct
Common Stock	Acquisiton	2021-09-17	142	$2.85	39,517	No	4	P	Direct
Common Stock	Acquisiton	2021-09-20	142	$2.82	39,659	No	4	P	Direct
Common Stock	Acquisiton	2021-09-21	142	$2.81	39,801	No	4	P	Direct
Common Stock	Acquisiton	2021-09-22	142	$2.76	39,943	No	4	P	Direct
Common Stock	Acquisiton	2021-09-23	142	$2.75	40,085	No	4	P	Direct
Common Stock	Acquisiton	2021-09-24	142	$2.74	40,227	No	4	P	Direct
Common Stock	Acquisiton	2021-09-27	142	$2.79	40,369	No	4	P	Direct
Common Stock	Acquisiton	2021-09-28	142	$2.76	40,511	No	4	P	Direct
Common Stock	Acquisiton	2021-09-29	142	$2.82	40,653	No	4	P	Direct
Common Stock	Acquisiton	2021-09-30	142	$2.72	40,795	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct

Footnotes

The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2021.